Drug therapy for advanced hepatocellular carcinoma: approach, controversy and progress
10.3760/cma.j.issn.1007-8118.2017.06.019
- VernacularTitle:晚期肝细胞癌的药物治疗:方法、争议与进展
- Author:
Haolin LI
;
Jing DONG
;
Meijuan YANG
;
Shizhong YANG
;
Weisheng YUAN
- Keywords:
Advanced hepatocellular carcinoma;
Chemotherapy;
Sorafenib;
Locoregional treatment;
Multimodal treatment
- From:
Chinese Journal of Hepatobiliary Surgery
2017;23(6):426-429
- CountryChina
- Language:Chinese
-
Abstract:
For unresectable advanced hepatocellular carcinoma (HCC),besides sorafenib,alternative drugs and treatment modalities are required.Clinical studies of hepatic arterial infusion chemotherapy (HAIC),transcatheter arterial chemoembolization (TACE),and system chemotherapy have shown favorable efficacy and tolerance in advanced HCC patients.In addition,the potential efficacy of sorafenib combined with focal treatment is also an interesting issue.As more therapies become available,decision-making for treating advanced HCC becomes increasingly complex.In our opinion,diverse treatment modalities should be utilized for the best interest of patients.Based on predictive biomarkers,we should develop a precise patient stratification system to select suitable candidates for each treatment modality in future studies,as is useful for improving prognosis of patients with advanced HCC.
